Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8439136 | 0.95 | CYP4F2 (0.53) | CYP4F2CYP4A11ALDH1A1LMNAMTNR1A | |
| SCHEMBL28212143 | 0.90 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL2821947 | 0.90 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL16575622 | 0.88 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1LMNAMTNR1A | |
| SCHEMBL29059884 | 0.88 | CTSS (0.43) | CYP4F2CYP4A11ALDH1A1LMNATDP1 | |
| SCHEMBL6987122 | 0.88 | MEN1 (0.47) | CYP4F2CYP4A11ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL6802490 | 0.87 | FOLH1 (0.51) | CYP4F2CYP4A11ALDH1A1LMNAMTNR1A | |
| SCHEMBL30339213 | 0.87 | FOLH1 (0.51) | CYP4F2CYP4A11ALDH1A1LMNAMTNR1A | |
| SCHEMBL6802449 | 0.85 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1LMNAMTNR1A | |
| SCHEMBL7286194 | 0.85 | CDYL (0.56) | CYP4F2CYP4A11MTNR1ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20050288273-A1 | Antibacterial agents | BOYER FREDERICK E JR | 2005-12-29 | — | — | US | disclosed |
| EP-1594865-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069832-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249583-A1 | HMG-CoA reductase inhibitors | HMGCR, LDLR, PCSK9 | CYP4F2 160/4885CYP4A11 75/4885ALDH1A1 1255/4885 |
| US-20050288273-A1 | Antibacterial agents | MRPL21, RPN2, FBL | CYP4F2 891/4885CYP4A11 2972/4885ALDH1A1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.